Drugs / ALA-1000
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04122755 | Sep 2019 → May 2021 | opiate dependence | Alar Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALA-1000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04122755 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of 1-fold ALA-1000 dose” NCT04122755 ↗ |